| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ICF45 |
| Uniprot No | Q9NWX6 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-269aa |
| 氨基酸序列 | MAKSKFEYVRDFEADDTCLAHCWVVVRLDGRNFHRFAEKHNFAKPNDSRALQLMTKCAQTVMEELEDIVIAYGQSDEYSFVFKRKTNWFKRRASKFMTHVASQFASSYVFYWRDYFEDQPLLYPPGFDGRVVVYPSNQTLKDYLSWRQADCHINNLYNTVFWALIQQSGLTPVQAQGRLQGTLAADKNEILFSEFNINYNNELPMYRKGTVLIWQKVDEVMTKEIKLPTEMEGKKMAVTRTRTKPVPLHCDIIGDAFWKEHPEILDEDS |
| 分子量 | 55.33 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人ICF45蛋白研究的示例文献(内容为模拟生成，仅供参考)：
1. **《ICF45重组蛋白在体外表征及其功能研究》**
*作者：Smith et al., 2018*
摘要：研究通过大肠杆菌表达系统成功制备重组人ICF45蛋白，验证其与DNA损伤修复通路中关键因子的相互作用，提示其在基因组稳定性中的潜在作用。
2. **《ICF45蛋白调控B淋巴细胞增殖的机制分析》**
*作者：Jiang et al., 2015*
摘要：利用CRISPR/Cas9技术构建ICF45缺陷型细胞模型，发现重组ICF45蛋白通过调控NF-κB信号通路影响B细胞增殖，可能与免疫缺陷疾病相关。
3. **《重组ICF45蛋白与HPV病毒E7蛋白的互作研究》**
*作者：Wang et al., 2020*
摘要：通过免疫共沉淀技术证实ICF45蛋白与人乳头瘤病毒(HPV)E7蛋白存在直接结合，可能参与病毒致癌机制，为抗病毒药物设计提供靶点。
4. **《高效重组ICF45蛋白纯化工艺开发》**
*作者：Chen et al., 2022*
摘要：优化真核表达系统(如昆虫细胞)中ICF45蛋白的分泌表达和层析纯化策略，提高产量与活性，满足结构生物学研究需求。
(注：以上文献信息为示例，具体研究需参考真实数据库如PubMed或Web of Science。)
**Background of Recombinant Human ICF45 Protein**
The recombinant human ICF45 protein, also known as Inhibitor of Growth Family Member 2 (ING2), is a nuclear protein involved in chromatin remodeling and epigenetic regulation. It belongs to the ING tumor suppressor family, characterized by a plant homeodomain (PHD) finger motif, which mediates interactions with histones and other chromatin-modifying complexes. ICF45/ING2 plays a critical role in DNA damage response, apoptosis, and cell cycle regulation by modulating histone acetylation and recruiting histone deacetylase (HDAC) complexes, such as the Sin3A/HDAC complex, to target genes.
Dysregulation of ICF45/ING2 has been linked to various cancers, including breast, prostate, and hepatocellular carcinomas, where its reduced expression correlates with tumor progression and poor prognosis. Recombinant ICF45 protein, produced via *E. coli* or mammalian expression systems, retains functional activity and is widely used in *in vitro* studies to investigate its tumor-suppressive mechanisms, including transcriptional regulation, chromatin dynamics, and interactions with oncogenic pathways. Its applications extend to drug discovery, particularly in identifying compounds that restore or enhance its activity in cancer models. Additionally, recombinant ICF45 serves as a tool for elucidating the molecular basis of chromatin remodeling and DNA repair, offering insights into therapeutic strategies targeting epigenetic dysregulation in diseases.
×
